Model-based analysis of Gd-BOPTA-induced MR signal intensity changes in cirrhotic rat livers

Investigative Radiology

Volumn 42, Issue 7, 2007, Pages 513-521

  Planchamp, Corinne ^a   Gex Fabry, Marianne ^a   Becker, Christoph D ^a   Pastor, Catherine M ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Contrast agent; Gd BOPTA; Liver cirrhosis; MRI; Population pharmacokinetic modeling

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOLINIUM PENTETATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG TRANSPORT; EXPERIMENTAL STUDY; IMAGE ANALYSIS; ISOLATED LIVER; LIVER; LIVER CELL; LIVER CIRRHOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOACTIVITY; RAT;

EID: 34250706946     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLI.0b013e318036b450     Document Type: Article

References (30)

1. Hamm B, Kirchin M, Pirovano G, et al. Clinical utility and safety of MultiHance in magnetic resonance imaging of liver cancer: results of multicenter studies in Europe and the USA. J Comput Assist Tomogr. 1999;23:S53-S60.
2. Manfredi R, Maresca G, Baron RL, et al. Gadobenate dimeglumine (BOPTA) enhanced MR imaging: patterns of enhancement in normal liver and cirrhosis. J Magn Reson Imaging. 1998;8:862-867.
3. Schneider G, Maas R, Kool SL, et al. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol. 2003;38:85-94.
4. Kuwatsuru R, Kadoya M, Ohtomo K, et al. Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors. Invest Radiol. 2001;36:632-641.
5. Grazioli L, Morana G, Kirchin MA, et al. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology. 2005;236:166-177.
6. Clément O, Siauve N, Lewin M, et al. Contrast agents in magnetic resonance imaging of the liver: present and future. Biomed Pharmacother. 1998;52:51-58.
7. Hahn PF, Saini S. Liver-specific MR imaging contrast agents. Radiol Clin North Am. 1998;36:287-297.
8. Pastor CM, Planchamp C, Pochon S, et al. Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation. Radiology. 2003;229:119-125.
9. Schuhmann-Giampieri G, Frenzel T, Schmitt-Willich H. Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. Drug Res. 1993;43:927-931.
10. Lorusso V, Arbughi T, Tirone P, et al. Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance). J Comput Assist Tomogr. 1999;23:S181-S194.
11. Pascolo L, Petrovic S, Cupelli F, et al. ABC protein transport of MRI contrast agents in canalicular rat liver plasma vesicles and yeast vacuoles. Biochem Biophys Res Commun. 2001;282:60-66.
12. de Haën C, Lorusso V, Tirone P. Hepatic transport of gadobenate dimeglumine in TR-rats. Acad Radiol. 1996;3:S452-S454.
13. +-independent organic anion transporting polypeptide (oatp-1) in rats with bile duct ligation. J Hepatol. 1997;27:1051-1056.
14. Planchamp C, Montet X, Frossard J-L, et al. Magnetic resonance imaging with hepatospecific contrast agents in cirrhotic rat livers. Invest Radiol. 2005;40:187-194.
15. 153Gd-BOPTA. Invest Radiol. 2005;40:705-714.
16. Aarons L. Population pharmacokinetics: theory and practice. Br J Clin Pharmacol. 1991;32:669-670.
17. Port RE, Knopp MV, Brix G. Dynamic contrast-enhanced MRI using Gd-DTPA: interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors. Magn Reson Med. 2001;45:1030-1038.
18. Spilker ME, Seng KY, Yao AA, et al. Mixture model approach to tumor classification based on pharmacokinetic measures of tumor permeability. J Magn Reson Imaging. 2005;22:549-558.
19. Planchamp C, Gex-Fabry M, Dornier C, et al. Gd-BOPTA transport into rat hepatocytes: pharmacokinetic analysis of magnetic resonance images using a hollow fiber bioreactor. Invest Radiol. 2004;39:506-515.
20. Port RE, Knopp MV, Hoffmann U, et al. Multicompartment analysis of gadolinium chelate kinetics: blood-tissue exchange in mammary tumors as monitored by dynamic MR imaging. J Magn Reson Imaging. 1999;10:233-241.
21. Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol. 1992;32:185-209.
22. Wagner JG. Integrated equations for several pharmacokinetic models. Biopharmaceutics and Relevant Pharmacokinetics. Halmilton, IL: Drug Intelligence Publications; 1971:292-296.
23. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol. 1997;32:780-796.
24. de Haën C, Cabrini M, Akhnana L, et al. Gadobenate dimeglumine 0.5 M solution for injection (MultiHance): pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr. 1999;23:S161-S168.
25. Giesel FL, von Tengg-Kobligk H, Wilkinson ID, et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents. Invest Radiol. 2006;41:222-228.
26. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dimeglumine (magnevist), gadobutrol (gadovist), and gadobenate dimeglumine (multihance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol. 2006;411:213-221.
27. Wersebe A, Wiskirchen J, Decker U, et al. Comparison of gadolinium-BOPTA and ferucarbotran-enhanced three-dimensional T1-weighted dynamic liver magnetic resonance imaging in the same patient. Invest Radiol. 2006;41:264-271.
28. Ivancevic MK, Zimine I, Lazeyras F, et al. FAST sequences optimization for contrast media pharmacokinetic quantification in tissue. J Magn Reson Imaging. 2001;14:771-778.
29. Vallée JP, Ivancevic M, Lazeyras F, et al. Use of high flip angle in T1-prepared FAST sequences for myocardial perfusion quantification. Eur Radiol. 2003;13:507-514.
30. Grazioli L, Morana G, Caudana R, et al. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings. Invest Radiol. 2000;35:25-34.